ES2902665T3 - Tratamiento del cáncer con combinación de plinabulina y taxano - Google Patents
Tratamiento del cáncer con combinación de plinabulina y taxano Download PDFInfo
- Publication number
- ES2902665T3 ES2902665T3 ES13895342T ES13895342T ES2902665T3 ES 2902665 T3 ES2902665 T3 ES 2902665T3 ES 13895342 T ES13895342 T ES 13895342T ES 13895342 T ES13895342 T ES 13895342T ES 2902665 T3 ES2902665 T3 ES 2902665T3
- Authority
- ES
- Spain
- Prior art keywords
- docetaxel
- plinabulin
- tumor
- treatment
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title claims abstract description 148
- 229950011498 plinabulin Drugs 0.000 title claims abstract description 139
- 206010028980 Neoplasm Diseases 0.000 title description 136
- 238000011282 treatment Methods 0.000 title description 68
- 229940123237 Taxane Drugs 0.000 title description 36
- 201000011510 cancer Diseases 0.000 title description 31
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title description 22
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 156
- 229960003668 docetaxel Drugs 0.000 claims abstract description 156
- 208000004235 neutropenia Diseases 0.000 claims abstract description 26
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 36
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 36
- 241001465754 Metazoa Species 0.000 description 42
- 239000004480 active ingredient Substances 0.000 description 38
- 239000003814 drug Substances 0.000 description 38
- 229940079593 drug Drugs 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 238000001990 intravenous administration Methods 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 21
- 238000001802 infusion Methods 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 230000004614 tumor growth Effects 0.000 description 18
- 230000004580 weight loss Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- -1 taxane compound Chemical class 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 230000002411 adverse Effects 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- 238000004364 calculation method Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 8
- 206010053759 Growth retardation Diseases 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 231100000001 growth retardation Toxicity 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000004066 vascular targeting agent Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010054094 Tumour necrosis Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000009104 chemotherapy regimen Methods 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000009533 lab test Methods 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010059282 Metastases to central nervous system Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 238000009597 pregnancy test Methods 0.000 description 3
- 238000009101 premedication Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 229940028652 abraxane Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000008384 ileus Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 239000000934 spermatocidal agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 description 1
- 229940077476 2,5-piperazinedione Drugs 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000012759 altered mental status Diseases 0.000 description 1
- 229940066481 amlodipine 10 mg Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008144 emollient laxative Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000001715 left bundle branch hemiblock Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002921 methylnaltrexone Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2902665T3 true ES2902665T3 (es) | 2022-03-29 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13895342T Active ES2902665T3 (es) | 2013-10-11 | 2013-10-11 | Tratamiento del cáncer con combinación de plinabulina y taxano |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (OSRAM) |
| EP (1) | EP3076972B1 (OSRAM) |
| JP (1) | JP6411523B2 (OSRAM) |
| KR (1) | KR102225371B1 (OSRAM) |
| CN (1) | CN105705148B (OSRAM) |
| AU (1) | AU2013402794B2 (OSRAM) |
| BR (1) | BR112016007946A2 (OSRAM) |
| CA (1) | CA2926771C (OSRAM) |
| DK (1) | DK3076972T3 (OSRAM) |
| ES (1) | ES2902665T3 (OSRAM) |
| IL (1) | IL244984B (OSRAM) |
| MX (1) | MX384751B (OSRAM) |
| MY (1) | MY185650A (OSRAM) |
| NZ (1) | NZ719049A (OSRAM) |
| RU (1) | RU2662298C2 (OSRAM) |
| SG (1) | SG11201602637QA (OSRAM) |
| WO (1) | WO2015051543A1 (OSRAM) |
| ZA (1) | ZA201602380B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201706281YA (en) * | 2015-02-12 | 2017-09-28 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| CN107530340B (zh) | 2015-03-06 | 2021-06-08 | 大连万春布林医药有限公司 | 治疗脑肿瘤的方法 |
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| JP7025416B2 (ja) * | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| MX2019009020A (es) * | 2017-02-01 | 2019-11-12 | Beyondspring Pharmaceuticals Inc | Metodo para reducir la neutropenia. |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals Inc | composições de plinabulina e seu uso |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| JP7350015B2 (ja) * | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| BR112020015758A2 (pt) * | 2018-02-01 | 2020-12-08 | Beyondspring Pharmaceuticals, Inc. | Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| CA3119768A1 (en) * | 2018-11-14 | 2020-05-22 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| US20240299377A1 (en) * | 2019-10-15 | 2024-09-12 | Beyondspring Pharmaceuticals, Inc. | Methods and compositions for treating iron disorders |
| EP4319751A4 (en) * | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| IL166628A0 (en) | 2002-08-02 | 2006-01-15 | Nereus Pharmaceuticals Inc | Dehydrophenyl lahistins and analogs thereof and the synthesis of dehydrophenyllahistins and analogs thereof |
| KR101228104B1 (ko) * | 2004-02-04 | 2013-02-01 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의합성방법 |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| EP2968536B1 (en) | 2013-03-13 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 MX MX2016004441A patent/MX384751B/es unknown
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active Active
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en not_active Ceased
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MY185650A (en) | 2021-05-27 |
| EP3076972B1 (en) | 2021-10-06 |
| ZA201602380B (en) | 2022-05-25 |
| KR102225371B1 (ko) | 2021-03-10 |
| AU2013402794B2 (en) | 2020-02-27 |
| CA2926771C (en) | 2022-07-05 |
| EP3076972A4 (en) | 2017-12-20 |
| US10596169B2 (en) | 2020-03-24 |
| NZ719049A (en) | 2020-06-26 |
| SG11201602637QA (en) | 2016-05-30 |
| BR112016007946A2 (pt) | 2017-09-12 |
| MX384751B (es) | 2025-03-14 |
| JP6411523B2 (ja) | 2018-10-24 |
| IL244984B (en) | 2022-05-01 |
| RU2016112608A (ru) | 2017-11-16 |
| DK3076972T3 (da) | 2022-01-03 |
| WO2015051543A1 (en) | 2015-04-16 |
| WO2015051543A8 (en) | 2016-04-21 |
| MX2016004441A (es) | 2016-10-28 |
| US20160250209A1 (en) | 2016-09-01 |
| EP3076972A1 (en) | 2016-10-12 |
| AU2013402794A1 (en) | 2016-05-12 |
| US20200281921A1 (en) | 2020-09-10 |
| KR20160078987A (ko) | 2016-07-05 |
| CN105705148A (zh) | 2016-06-22 |
| JP2016536352A (ja) | 2016-11-24 |
| CN105705148B (zh) | 2021-03-23 |
| CA2926771A1 (en) | 2015-04-16 |
| IL244984A0 (en) | 2016-05-31 |
| RU2662298C2 (ru) | 2018-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2902665T3 (es) | Tratamiento del cáncer con combinación de plinabulina y taxano | |
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| ES2862340T3 (es) | Nuevo uso antitumoral de cabazitaxel | |
| JP2011511072A (ja) | 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用 | |
| JP2014132009A5 (OSRAM) | ||
| KR20130140032A (ko) | 암을 치료하는 방법들 | |
| JP2016528217A (ja) | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 | |
| Kollmannsberger et al. | Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179) | |
| JP2013521338A (ja) | 小細胞肺癌を治療するための方法 | |
| US8173686B2 (en) | Use of picoplatin to treat colorectal cancer | |
| ES2854298T3 (es) | Tratamiento con SYD985 de pacientes con cáncer resistentes a T-DM1 | |
| US8168661B2 (en) | Use of picoplatin to treat colorectal cancer | |
| WO2010132596A1 (en) | Use of picoplatin to treat colorectal cancer | |
| JP2018199726A (ja) | プリナブリン及びタキサンの組合せがん治療 | |
| Scagliotti et al. | Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer | |
| US8168662B1 (en) | Use of picoplatin to treat colorectal cancer | |
| HK1229712B (en) | Cancer treatment with combination of plinabulin and taxane | |
| WO2025232873A1 (zh) | 多西他赛白蛋白组合物治疗胃癌或胃食管结合部癌的用途 | |
| US20120156199A1 (en) | Use of picoplatin to treat colorectal cancer | |
| HK1155089A (en) | Use of picoplatin and bevacizumab to treat colorectal cancer | |
| TW201336493A (zh) | 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎小兒藥用途 |